- Home
- WRN vs CRGX Comparison
WRN vs CRGX Comparison
Compare WRN & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRN
- CRGX
- Stock Information
- Founded
- WRN 2006
- CRGX 2021
- Country
- WRN Canada
- CRGX United States
- Employees
- WRN N/A
- CRGX N/A
- Industry
- WRN Metal Mining
- CRGX
- Sector
- WRN Basic Materials
- CRGX
- Exchange
- WRN Nasdaq
- CRGX Nasdaq
- Market Cap
- WRN 228.0M
- CRGX 190.0M
- IPO Year
- WRN N/A
- CRGX 2023
- Fundamental
- Price
- WRN $1.23
- CRGX $4.27
- Analyst Decision
- WRN Strong Buy
- CRGX Hold
- Analyst Count
- WRN 1
- CRGX 7
- Target Price
- WRN $4.00
- CRGX $4.67
- AVG Volume (30 Days)
- WRN 421.9K
- CRGX 647.1K
- Earning Date
- WRN 08-08-2025
- CRGX 08-11-2025
- Dividend Yield
- WRN N/A
- CRGX N/A
- EPS Growth
- WRN N/A
- CRGX N/A
- EPS
- WRN N/A
- CRGX N/A
- Revenue
- WRN N/A
- CRGX N/A
- Revenue This Year
- WRN N/A
- CRGX $58.18
- Revenue Next Year
- WRN N/A
- CRGX N/A
- P/E Ratio
- WRN N/A
- CRGX N/A
- Revenue Growth
- WRN N/A
- CRGX N/A
- 52 Week Low
- WRN $0.90
- CRGX $3.00
- 52 Week High
- WRN $1.42
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- WRN 57.42
- CRGX 45.02
- Support Level
- WRN $1.32
- CRGX $4.33
- Resistance Level
- WRN $1.39
- CRGX $4.48
- Average True Range (ATR)
- WRN 0.06
- CRGX 0.19
- MACD
- WRN 0.01
- CRGX -0.02
- Stochastic Oscillator
- WRN 59.68
- CRGX 21.14
About WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project).
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.